EC Neurology

Review Article Volume 17 Issue 3 - 2025

Role of Gut Microbiota in Neuropathy Development

Ahed J Alkhatib1,2,3*, Mustafa Ahmad Al-Shehabat4, Dania Mustafa Al-Shehabat5, Aya Mustafa Al-Shehabat6 and Adam Mustafa Al-Shehabat6

1Retired, Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan 2International Mariinskaya Academy, Department of Medicine and Critical Care, Department of Philosophy, Academician Secretary of Department of Sociology, Jordan 3Cypress International Institute University, Texas, USA 4Department of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, Jordan 5King Abdulla University Hospital, Jordan 6Faculty of Medicine, Jordan University of Science and Technology, Jordan

*Corresponding Author: Ahed J Alkhatib, Retired, Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan.
Received: January 09, 2025; Published: February 13, 2025



The constant interplay between the gut microbiota and the nervous system has led to a new field of research, primarily focusing on changes in the microbial community ('dysbiosis') as a contributing factor to neurological disease and pain development. It is here that the focus of the present narrative review is aimed. Discussed will be the relationship between gut microbiota and neurological health. After detailing the nature and origins of oral neuropathic pain and chronic somatic pain, the weight of evidence linking these diseases to gut dysbiosis is highlighted. Finally, the promising therapeutic implications of re-establishing normal gut microbiota composition by probiotics or Fecal Microbiota Transplantation (FMT) are touched upon.

Symptoms related to the impairment of peripheral nerves constitute chronic disorders, often of high prevalence. Although the etiology is different, neuropathic pain conditions lead to long-term treatment deficits. This likely reflects an insufficient knowledge of the etiology of neuropathic pain conditions. Recently, an association between the presence of neuropathic pain and conspicuous changes in gut bacteria ('dysbiosis') was noticed. As a variety of bacterial strains are known to induce an inflammatory response with sequential pain symptom appearance, inflammation in the intestine gave a plausible explanation for the observations.

 Keywords: Gut; Microbiota; Neuropathy; Development; Nervous System; Microbes

  1. Zhang K., et al. “Integrating plasma metabolomics and gut microbiome to reveal the mechanisms of Huangqi Guizhi Wuwu Decoction intervene diabetic peripheral neuropathy”. Journal of Ethnopharmacology3 (2024): 117301.
  2. Mario A Saporta., et al. “Chapter 11 - Peripheral neuropathies. Thoughts on teaching about the neurobiology of diseases”. Neurobiology of Brain Disorders, Second Edition (2023): 165-184.
  3. Tokuçoğlu F and Diniz G. “Peripheral Neuropathies”. In Clues for Differential Diagnosis of Neuromuscular Disorders. Cham: Springer International Publishing (2023): 125-168.
  4. Alkhatib AJ. “New insights to diabetes: Is diabetes a metabolic disorder or a neurological disease?” International Journal of Diabetes and Metabolic Disorders1 (2019): 2.
  5. Alzu'bi MF., et al. “Studying the association of metformin dose with peripheral neuropathy in diabetic patients at Jordanian Royal Medical Services”. European Scientific Journal6 (2016): 22.
  6. Wang W., et al. “Prevalence and risk factors of diabetic peripheral neuropathy: A population‐based cross‐sectional study in China”. Diabetes/Metabolism Research and Reviews8 (2023): e3702.
  7. Oliveira JT., et al. “Neuron-Schwann cell interactions in peripheral nervous system homeostasis, disease, and preclinical treatment”. Frontiers in Cellular Neuroscience 17 (2023): 1248922.
  8. Nabiuni M., et al. “Investigation of types of neuropathies in the brain and nerves”. Eurasian Journal of Chemical, Medicinal and Petroleum Research5 (2023): 1-15.
  9. Yang J., et al. “Gut microbiota modulate distal symmetric polyneuropathy in patients with diabetes”. Cell Metabolism9 (2023): 1548-1562.
  10. Sloan G., et al. “Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy”. Nature Reviews. Endocrinology7 (2021): 400-420.
  11. Slangen R., et al. “Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial”. Diabetes Care11 (2014): 3016-3024.
  12. Pop-Busui R., et al. “Diabetic neuropathy: A position statement by the American Diabetes association”. Diabetes Care1 (2017): 136-154.
  13. Metwaly A., et al. “Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders”. Nature Reviews Gastroenterology and Hepatology 6 (2022): 383-397.
  14. Pane K., et al. “Role of gut microbiota in neuropathy and neuropathic pain states: A systematic preclinical review”. Neurobiology of Disease 170 (2022): 105773.
  15. Tansey MG., et al. “Inflammation and immune dysfunction in Parkinson disease”. Nature Reviews. Immunology11 (2022): 657-673.
  16. Tilg H., et al. “The intestinal microbiota fuelling metabolic inflammation”. Nature Reviews. Immunology 1 (2020): 40-54.
  17. Fan Y and Pedersen O. “Gut microbiota in human metabolic health and disease”. Nature Reviews. Microbiology1 (2021): 55-71.
  18. Morais LH., et al. “The gut microbiota-brain axis in behaviour and brain disorders”. Nature Reviews. Microbiology4 (2021): 241-255.
  19. Defaye M., et al. “Microbiota: a novel regulator of pain”. Journal of Neural Transmission4 (2020): 445-465.
  20. B Lin., et al. “Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy”. Journal of Headache and Pain 1 (2020): 103.
  21. HC Lehmann., et al. “Diagnosis of peripheral neuropathy”. Neurological Research and Practice 2 (2020): 20.
  22. G Chen., et al. “Microglia in pain: detrimental and protective roles in pathogenesis and resolution of pain”. Neuron6 (2018): 1292-1311.
  23. Gaykema RP., et al. “Brain response to cecal infection with Campylobacter jejuni: analysis with Fos immunohistochemistry”. Brain, Behavior, and Immunity3 (2004): 238-245.
  24. Wong ML., et al. “Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition”. Molecular Psychiatry6 (2016): 797-805.
  25. Braniste V., et al. “The gut microbiota influences blood-brain barrier permeability in mice”. Science Translational Medicine263 (2014): 263ra158.
  26. Corriero A., et al. “Gut microbiota modulation and its implications on neuropathic pain: a comprehensive literature review”. Pain and Therapy1 (2023): 33-51.
  27. Brodal P. “The central nervous system”. Oxford university Press (2010).
  28. Priori D., et al. “The olfactory receptor OR51E1 is present along the gastrointestinal tract of pigs, co-localizes with enteroendocrine cells and is modulated by intestinal microbiota”. PloS one6 (2015): e0129501.
  29. Caspani G and Swann J. “Small talk: microbial metabolites involved in the signaling from microbiota to brain”. Current Opinion in Pharmacology 48 (2019): 99-106.
  30. Yano JM., et al. “Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis”. Cell2 (2015): 264-276.
  31. Berger M., et al. “The expanded biology of serotonin”. Annual Review of Medicine 60 (2009): 355-366.
  32. Rutsch A., et al. “The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology”. Frontiers in Immunology 11 (2020): 604179.
  33. Corriero A., et al. “Gut microbiota modulation and its implications on neuropathic pain: a comprehensive literature review”. Pain and Therapy1 (2024): 33-51.
  34. Alkhatib AJ. “Immunology and microbes”. In the role of microbes in autoimmune diseases: new mechanisms of microbial initiation of autoimmunity. Singapore: Springer Nature Singapore (2022): 9-19.
  35. Yamani IA., et al. “Exploring the role of neurotoxicants (iNOS and HSP90) in the development of psychiatric diseases”. Pakistan Journal of Life and Social Sciences 2 (2024): 6931-6945.
  36. Alkhatib AJ. “New perspectives of autoimmunity diseases and microbiome: Etiology and treatment”. Acta Scientific Pharmaceutical Sciences10 (2018): 12-14.
  37. Alkhatib AJ. “The role of microbes in autoimmune diseases”. Springer, Singapore (2022).
  38. Kigerl KA., et al. “Gut dysbiosis impairs recovery after spinal cord injury”. The Journal of Experimental Medicine12 (2016): 2603-2620.

Ahed J Alkhatib., et al. “Role of Gut Microbiota in Neuropathy Development”. EC Neurology  17.3 (2025): 01-06.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net